Can I give Augmentin (amoxicillin‑clavulanate) 625 mg three times daily to a 15‑year‑old weighing 48 kg for a urinary tract infection with flank pain and dysuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Give Augmentin 625 mg TID to a 15-Year-Old (48 kg) for UTI with Flank Pain and Dysuria?

Yes, Augmentin 625 mg three times daily is an appropriate and safe dose for this 15-year-old patient with suspected pyelonephritis, though the clinical presentation with flank pain suggests you should consider whether this represents upper tract disease requiring more aggressive initial therapy.

Dose Appropriateness

The dose of 625 mg TID provides approximately 39 mg/kg/day of amoxicillin (625 mg × 3 = 1875 mg total daily amoxicillin for a 48 kg patient). This falls within the acceptable pediatric dosing range:

  • Standard pediatric UTI dosing: 20–40 mg/kg/day divided in 3 doses 1
  • Your patient's dose: 39 mg/kg/day (appropriate)
  • Maximum recommended: Up to 90 mg/kg/day for severe infections 2

The FDA label confirms amoxicillin-clavulanate is dosed at 20–40 mg/kg/day in 3 divided doses for pediatric UTI 2, and your proposed regimen meets this standard.

Critical Clinical Decision: Upper vs. Lower Tract Disease

The presence of flank pain is concerning for pyelonephritis (upper tract infection), not simple cystitis. This distinction fundamentally changes your management approach:

If This is Pyelonephritis (Likely Given Flank Pain):

  1. Consider initial parenteral therapy if the patient appears toxic, has persistent vomiting, or cannot tolerate oral intake 3, 1

    • Single dose of IV ceftriaxone (50–75 mg/kg, max 1 g) followed by oral therapy is reasonable 3, 1
    • Alternatively, start oral therapy if patient is well-appearing and can tolerate oral intake 1
  2. Oral amoxicillin-clavulanate is acceptable for outpatient pyelonephritis management in adolescents who are:

    • Well-appearing
    • Able to tolerate oral intake
    • Reliable for follow-up 4, 3, 1
  3. Treatment duration: 7–14 days total 1, 5

    • Recent evidence suggests 7 days may be sufficient for uncomplicated cases 5
    • The traditional 10-day course remains standard 1

If This is Simple Cystitis (Less Likely Without Flank Pain):

  • Amoxicillin-clavulanate for 3–5 days would be adequate 4, 3, 5
  • However, flank pain argues against simple cystitis

Guideline-Based Positioning

Amoxicillin-clavulanate is explicitly listed as an appropriate choice for pediatric UTI across multiple guidelines:

  • WHO 2024: Lists amoxicillin-clavulanate as a first-choice option for lower UTI 4
  • IDSA/ESMID 2011: Recommends it as an alternative when other agents cannot be used, though notes β-lactams have "inferior efficacy" compared to fluoroquinolones or TMP-SMX for uncomplicated cystitis 3
  • AAP 2011: Explicitly includes it in empiric oral therapy tables at 20–40 mg/kg/day in 3 doses 1

Important caveat: The IDSA guideline notes that β-lactams should be used "with caution" for uncomplicated cystitis due to somewhat lower efficacy 3. However, for pyelonephritis (which your patient likely has), amoxicillin-clavulanate is more clearly supported, particularly in pediatric populations 1.

Local Resistance Patterns Matter

You must know your local E. coli resistance rates to amoxicillin-clavulanate before using it empirically:

  • Guidelines recommend empiric agents have <10% resistance for pyelonephritis and <20% for cystitis 4
  • If local resistance exceeds these thresholds, consider alternatives (TMP-SMX, cephalosporins, or fluoroquinolones) 4, 3
  • Recent data shows amoxicillin-clavulanate maintains reasonable activity against many ESBL-producing organisms in urine 6, 7

Practical Management Algorithm

  1. Assess severity: Is the patient toxic-appearing, vomiting, or unable to take oral medications?

    • Yes → Admit, give IV ceftriaxone or cefotaxime 1
    • No → Proceed with oral therapy
  2. Obtain urine culture before starting antibiotics 3, 5

  3. Start empiric therapy with amoxicillin-clavulanate 625 mg TID

    • Take at the start of meals to minimize GI side effects 2
    • Plan for 7–10 days total duration 1, 5
  4. Reassess at 48–72 hours:

    • If fever persists or symptoms worsen → consider IV therapy or alternative oral agent 1
    • If improving → continue oral therapy to complete course
  5. Adjust based on culture results when available 3, 5

Common Pitfalls to Avoid

  • Don't use nitrofurantoin for pyelonephritis—it doesn't achieve adequate tissue concentrations despite excellent urinary levels 1
  • Don't assume all UTIs are the same—flank pain = pyelonephritis = longer treatment and closer monitoring
  • Don't ignore local resistance data—empiric therapy must be guided by your institution's antibiogram
  • Don't forget to obtain imaging (renal ultrasound) if this is a first febrile UTI or if patient doesn't improve 1

Supporting Evidence from Clinical Studies

Recent pediatric data supports amoxicillin-clavulanate effectiveness:

  • 80–96% cure rates in pediatric UTI 8, 9
  • Superior outcomes compared to ceftriaxone in children under 5 years with febrile UTI 10
  • Effective even against some ESBL-producing organisms when used at adequate doses 7

Bottom line: Your proposed dose is appropriate, but ensure you're treating this as pyelonephritis (not simple cystitis) given the flank pain, obtain cultures, know your local resistance patterns, and plan for 7–10 days of therapy with close follow-up.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.